Replies to post #244424 on Biotech Values

[dewophile]

Yes; however, the HBs seroconverion makes an off-therapy relapse considerably less likely than merely having undetectable HBsAg at the end of treatment

my understanding is that the overwhelming majority who get to undetectable seroconvert so the fact these patients have surface antibodies vs merely loss of surface antigen is relatively meaningless

[dewophile]

Yes; however, the HBs seroconverion makes an off-therapy relapse considerably less likely than merely having undetectable HBsAg at the end of treatment

https://events-distribution.easl.eu/from.storage?image=XuxJjSOSJud6SrESrXs_xT__lX7lqBfPJM3PwfWfYrLmyADi8_WVcpnWMbrjgdUZ0

Of the 11 with HBsAg loss, 6 participants...sustained HBsAg loss and
remained anti-HBs positive for at least 24 weeks post-EOT. Among those who achieved
HBsAg loss, anti-HBs titers > 500 mIU/mL at EOT predicted achieving sustained loss of
HBsAg at 24 weeks post-EOT.